Brain-Computer Interface Startup Funding
In our updated market reports, you will find everything you need
SUMMARY
This page analyzes every publicly disclosed equity round raised by pure-play or near-pure-play Brain-Computer Interface companies between August 2024 and July 2026, a 24-month window covering every geography. We only kept disclosed equity rounds of $300K or more, and excluded broader neurotechnology companies where BCI was not the core business.
Over this period, fundraising in the Brain-Computer Interface market was small in deal count but very large in capital intensity. The dataset includes 16 disclosed deals, 14 unique companies, and $2.06B raised.
Capital in the Brain-Computer Interface market is highly concentrated. The largest deal alone represents 31.56% of total capital, the top 3 deals reach 57.69%, and the top 5 deals reach 78.57%.
The market is defined by large platform rounds. Half of all disclosed deals were above $50M, and 37.50% were above $100M, which is unusually high for a market with several Seed and Series A rounds.
Monthly deal flow is episodic rather than steady. The dataset averages 0.67 deals per month over 24 months, while the median month had zero disclosed deals.
Implantable BCIs lead the Brain-Computer Interface market by capital raised. The category captured $1.13B, or 54.75% of disclosed capital, from 6 deals.
North America dominates the market geographically. It captured $1.57B, or 76.23% of disclosed capital, and produced 10 of the 16 disclosed deals.
The Brain-Computer Interface market looks more late-stage than early-stage by dollars. Series C, Series D+, and Growth Equity rounds captured $1.54B, or 74.82% of all disclosed capital.
Early-stage activity is still visible, but it is distorted by exceptional rounds. Seed, Series A, and Series B represented half of all deals, but only 25.18% of total capital.
Repeat investor activity is narrow. The most visible repeat investors were Golden Falcon Capital around Subsense, and Qiming Venture Partners, OrbiMed, Lilly Asia Ventures, FountainBridge Capital, and Tencent around StairMed.
What are all the funding deals in the Brain-Computer Interface market from August 2024 to July 2026?
The table below lists every disclosed equity round raised by pure-play or near-pure-play Brain-Computer Interface companies between August 2024 and July 2026. We count as pure-play Brain-Computer Interface companies those focused on implantable BCIs, non invasive BCIs, neuroprosthetics, neural signal processing, BCI software platforms, or clinical neurotechnology.
Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors when disclosed, and the announcement source.
| Company | What they do | Category | Date | Stage | Deal size | Region | Main investors | Source |
|---|---|---|---|---|---|---|---|---|
| INBRAIN Neuroelectronics | Graphene-based implantable BCI therapeutics platform designed to decode and modulate neural activity for neurological disorders | Clinical Neurotechnology | Oct 2024 | Series B | $50M | Europe | Undisclosed in dataset | BusinessWire |
| Precision Neuroscience | Minimally invasive cortical-interface BCI designed to help people with paralysis control computers and digital devices | Implantable BCIs | Dec 2024 | Series C | $102M | North America | Undisclosed in dataset | Yahoo Finance |
| StairMed | Minimally invasive implantable brain-machine interface systems for paralysis, aphasia, assistive-device control, and neural rehabilitation | Implantable BCIs | Feb 2025 | Series B | $48M | Asia-Pacific | Qiming Venture Partners; OrbiMed; Lilly Asia Ventures; FountainBridge Capital | China Daily |
| Subsense | Non-surgical nanoparticle-based bidirectional BCI platform designed to record and modulate brain activity without implanted electrodes | Non Invasive BCIs | Feb 2025 | Seed | $17M | North America | Golden Falcon Capital | BioSpace |
| brain.space | Brain-data platform using standardized EEG and signal-processing infrastructure to model, predict, and interpret human cognitive states | Neural Signal Processing | Mar 2025 | Series A | $11M | Middle East | Undisclosed in dataset | PR Newswire |
| Phantom Neuro | Neural interface technology for intuitive control of prosthetics, robotics, and human-machine interfaces | Neuroprosthetics | Apr 2025 | Series A | $19M | North America | Ottobock | PR Newswire |
| Neuralink | Implantable high-bandwidth brain interface platform intended to restore independence and expand brain-computer interaction | Implantable BCIs | Jun 2025 | Series D+ | $650M | North America | Undisclosed in dataset | Neuralink |
| Synchron | Endovascular, non-open-brain BCI platform using the Stentrode system to translate brain activity into digital commands | Implantable BCIs | Nov 2025 | Series D+ | $200M | North America | Undisclosed in dataset | BusinessWire |
| Subsense | Non-surgical nanoparticle-based bidirectional BCI platform designed to record and modulate brain activity without implanted electrodes | Non Invasive BCIs | Dec 2025 | Seed | $10M | North America | Golden Falcon Capital | BusinessWire |
| Neurable | Noninvasive everyday BCI technology integrating brain-signal processing into consumer devices such as headphones and wearables | Consumer Neurotech | Dec 2025 | Series A | $35M | North America | Undisclosed in dataset | BusinessWire |
| BrainCo | Noninvasive BCI company developing brain-computer interface products including rehabilitation and intelligent prosthetic systems | Rehabilitation Interfaces | Jan 2026 | Growth Equity | $286.3M | Asia-Pacific | Undisclosed in dataset | Yicai Global |
| Merge Labs | Noninvasive BCI startup using molecules, ultrasound, hardware, biology, and AI to connect with neurons without brain implants | Non Invasive BCIs | Jan 2026 | Seed | $252M | North America | OpenAI-related investors and Sam Altman-linked backers | Wired |
| Science Corporation | Full-stack neural engineering company commercializing PRIMA, a BCI retinal implant for vision restoration | Neuroprosthetics | Mar 2026 | Series C | $230M | North America | Undisclosed in dataset | Science Corporation |
| Gestala | Noninvasive ultrasound-based BCI startup developing technology to stimulate and eventually read brain activity without surgery | Non Invasive BCIs | Mar 2026 | Seed | $21.69M | Asia-Pacific | Undisclosed in dataset | MassDevice |
| StairMed | Minimally invasive implantable brain-machine interface systems for paralysis, aphasia, assistive-device control, and neural rehabilitation | Implantable BCIs | Apr 2026 | Growth Equity | $72.7M | Asia-Pacific | Alibaba; Tencent; Qiming Venture Partners; OrbiMed; Lilly Asia Ventures; FountainBridge Capital | PR Newswire |
| Axoft | Bio-inspired implantable BCI platform using soft neural-interface materials for high-resolution brain recording and stimulation | Implantable BCIs | Apr 2026 | Series A | $55M | North America | Undisclosed in dataset | BusinessWire |
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this Brain-Computer Interface funding tracker by reviewing every publicly disclosed equity round raised by pure-play or near-pure-play Brain-Computer Interface companies between August 2024 and July 2026. A company counts as pure-play when more than 80% of its activity is dedicated to recording, interpreting, or stimulating brain signals to control devices or restore function.
We applied four filters to build the dataset. First, we only included equity rounds, so grants, debt-only financings, non-dilutive awards, acquisitions, and IPO filings are excluded. Second, we only counted rounds of $300K or more. Third, we only kept pure-play or near-pure-play Brain-Computer Interface companies. And fourth, every entry had to be confirmed by a direct company announcement, a press release, or a tier-1 media report, with the source URL preserved for every row.
The final dataset contains 16 disclosed deals across 14 unique companies, and every average, median, share, and concentration ratio is computed on that disclosed sample. Privately raised rounds that were never publicly announced are necessarily missing, which is a known limitation of any public-only Brain-Computer Interface funding tracker.
How active has fundraising been in the Brain-Computer Interface market?
As of July 2026, fundraising in the Brain-Computer Interface market has been sparse by deal count but intense by dollars. Over the past 24 months, companies raised 16 disclosed equity rounds and $2.06B combined, which works out to 0.67 deals per month.
The Brain-Computer Interface market is not a high-frequency funding market. The median number of deals per month was zero, which means most calendar months had no qualifying disclosed equity round.
Dollar flow is also episodic. The market averaged $85.82M raised per month, but the median monthly capital raised was zero, showing how much the total depends on a few announcement clusters.
This rhythm fits the structure of Brain-Computer Interface development. Companies usually need technical milestones, regulatory progress, clinical evidence, or exceptional founder credibility before investors write large checks.
How concentrated has fundraising been in the Brain-Computer Interface market?
As of July 2026, fundraising in the Brain-Computer Interface market has been extremely concentrated. Over the past 24 months, the largest deal represented 31.56% of all disclosed capital, the top 3 deals reached 57.69%, and the top 5 reached 78.57%.
Neuralink’s $650M Series E alone is the clearest example. That one round is larger than all sub-$50M rounds in the dataset combined, and it sets the tone for the market’s headline number.
The top 10 deals represented 94.48% of all disclosed capital. That means most dollar-based conclusions about the Brain-Computer Interface market are really conclusions about a small set of large platform financings.
This concentration makes average funding a weak indicator. The average round size was $128.73M, but the median was $52.5M, so the average is heavily pulled upward by outliers.
How much of the Brain-Computer Interface funding signal is driven by outliers?
As of July 2026, the Brain-Computer Interface funding signal is driven heavily by outliers. Over the past 24 months, 8 of 16 disclosed rounds were above $50M, and 6 were above $100M.
Rounds above $50M accounted for half of all disclosed deals, but they controlled almost the entire direction of the market. Excluding those larger rounds, total disclosed capital falls to only $211.69M.
That means the sub-$50M Brain-Computer Interface market represented just 10.28% of total capital. Smaller rounds exist, but they do not determine the strategic narrative of the market.
The main reading rule is simple: do not treat the total as a broad liquidity signal. It is mostly a signal that a few companies can raise very large rounds when they combine strong teams, clinical ambition, and credible technical paths.
Is the Brain-Computer Interface market broad with many targets, or narrow with few fundable companies?
As of July 2026, the Brain-Computer Interface market is narrow rather than broad. Over the past 24 months, only 14 unique companies raised qualifying disclosed equity rounds.
That narrowness matters because the market’s capital total is not supported by a long tail of startups. It is supported by repeat financings and large checks into a limited set of companies.
Only 3 of the 16 deals were first financings. The remaining rounds were follow-ons, which suggests investors are mostly backing companies that have already cleared an earlier credibility threshold.
Subsense and StairMed both raised twice during the period. These repeat-financing cases show that investors can re-underwrite quickly when a company sits inside a strategic technical theme.
Is Brain-Computer Interface mostly an early-stage formation market or a late-stage scaling market?
As of July 2026, the Brain-Computer Interface market behaves more like a late-stage scaling market than a broad early-stage formation market. Over the past 24 months, late-stage rounds captured $1.54B, or 74.82% of disclosed capital.
Early-stage rounds, defined as Seed, Series A, and Series B, still accounted for 10 of 16 deals. But those rounds captured only $518.69M, or 25.18% of total capital.
The Seed category is especially distorted by Merge Labs. Seed rounds totaled $300.69M, but a single $252M Merge Labs financing made the stage look much larger than ordinary Seed activity would suggest.
Series D+ was the largest stage by dollars, with $850M raised across 2 deals. That reflects a market where mature clinical and platform narratives receive much deeper checks than discovery-stage ideas.
Which categories attract the most investor attention in Brain-Computer Interface?
As of July 2026, Implantable BCIs attract the most investor attention in the Brain-Computer Interface market. Over the past 24 months, the category raised $1.13B across 6 deals, equal to 54.75% of all disclosed capital and 37.50% of deals.
Implantable BCIs include several of the market’s largest companies, including Neuralink, Synchron, Precision Neuroscience, StairMed, and Axoft. The category benefits from a clearer path to high-fidelity neural signal capture.
Non Invasive BCIs ranked second by capital, with $300.69M across 4 deals. The category accounted for 25.00% of deals but only 14.60% of capital, showing more experimentation than scaled conviction.
Neuroprosthetics also mattered, with $249M across 2 deals. Science Corporation and Phantom Neuro show that investors still reward BCI use cases tied to restoration, vision, prosthetics, and functional independence.
Which categories attract disproportionately large checks in the Brain-Computer Interface market?
As of July 2026, Rehabilitation Interfaces attracted the most disproportionately large checks in the Brain-Computer Interface market. Over the past 24 months, the category had only 1 deal but captured $286.3M, giving it a capital-share-to-deal-share ratio of 2.22.
This result is driven entirely by BrainCo. Its $286.3M growth financing made Rehabilitation Interfaces look large despite having only one qualifying disclosed deal.
Implantable BCIs were the broadest large-check category. Their capital-share-to-deal-share ratio was 1.46, which means the category captured more dollars than its deal count alone would imply.
Neural Signal Processing sat at the other end of the spectrum. It represented 6.25% of deals but only 0.53% of capital, confirming that pure data-layer BCI companies have not yet attracted hardware-scale financing.
Which geographies matter most for fundraising in the Brain-Computer Interface market?
As of July 2026, North America is the geography that matters most for Brain-Computer Interface fundraising. Over the past 24 months, the region raised $1.57B, or 76.23% of disclosed capital, across 10 deals.
North America also had the deepest check sizes. Its average deal size was $157M and its median deal size was $78.5M, both supported by Neuralink, Synchron, Merge Labs, Science Corporation, and Precision Neuroscience.
Asia-Pacific ranked second with $428.69M across 4 deals. The region captured 20.81% of capital and 25.00% of deals, led by BrainCo and two StairMed financings.
Europe and the Middle East were visible but small in the quantified dataset. Europe had INBRAIN’s $50M Series B, while the Middle East had brain.space’s $11M Series A.
Is the Brain-Computer Interface opportunity set broad or concentrated in one hub?
As of July 2026, the Brain-Computer Interface opportunity set is concentrated in one main hub with a meaningful second region. Over the past 24 months, North America captured 76.23% of capital and 62.50% of deals.
Asia-Pacific is the second pole, but it is less broad than North America in this dataset. Its 4 disclosed deals came from BrainCo, StairMed, and Gestala, with China driving most of the regional signal.
Europe had only one qualifying disclosed round, and the Middle East also had one. Latin America and Africa had no qualifying disclosed equity rounds during the period.
This footprint suggests that Brain-Computer Interface company formation still depends on concentrated access to neurosurgery, frontier hardware talent, regulatory pathways, and specialized investors.
Is Brain-Computer Interface a market of small experiments or scaled financings?
As of July 2026, the Brain-Computer Interface market is a market of scaled financings, not small experiments. Over the past 24 months, 8 of 16 disclosed rounds were above $50M.
The smaller end of the market is limited. There were no qualifying disclosed deals below $5M, 4 deals between $5M and $20M, and 4 deals between $20M and $50M.
The median round size was $52.5M, which already puts the typical disclosed round near megaround territory. The average round size was much higher, at $128.73M, because the largest rounds dominate the calculation.
Six rounds were above $100M, representing 37.50% of all disclosed deals. In Brain-Computer Interface, megarounds are not rare noise; they are a defining feature of credible platform competition.
Who are the investors that appear the most in Brain-Computer Interface fundraising?
As of July 2026, repeat investors in the Brain-Computer Interface market were limited and clustered. Over the past 24 months, the clearest repeat activity came from investors that backed Subsense twice or StairMed twice.
Golden Falcon Capital appeared in both Subsense financings. That repeat pattern reflects continued support for a non-surgical nanoparticle-based bidirectional BCI approach.
Qiming Venture Partners, OrbiMed, Lilly Asia Ventures, and FountainBridge Capital appeared in both StairMed rounds. Tencent also appeared around StairMed’s financing history, including the April 2026 strategic round.
This investor pattern is important because it is not broad generalist repetition. The Brain-Computer Interface market still looks too technical, regulated, and specialized for many investors to participate repeatedly across multiple companies.
One caveat matters: round announcements rarely disclose individual investor check sizes. Investor repetition should therefore be read as participation frequency, not as dollars personally committed.
INSIGHTS
The insights below come from reviewing every disclosed equity round in the Brain-Computer Interface market between August 2024 and July 2026. They are not row-by-row summaries. They are the reusable patterns that kept showing up across the 16-deal dataset, and they are meant to stay useful when reading any future Brain-Computer Interface funding announcement.
The Brain-Computer Interface market is not funding like a normal early venture category. Late-stage and growth rounds captured 74.82% of capital, even though Seed and Series A rounds were still visible. Investors are concentrating dollars behind companies that can survive clinical, regulatory, manufacturing, and implantation-risk hurdles.
Average round size is a misleading signal in Brain-Computer Interface. The average disclosed round was $128.73M, which is 2.45 times the $52.5M median. A few platform-scale rounds define the market’s capital intensity far more than the typical company does.
Neuralink changes the market headline by itself. Its $650M Series E represented 31.56% of all disclosed capital. Any analysis that does not separate Neuralink risks confusing one exceptional financing capacity with broad market liquidity.
The top 5 deals explain most of the market. They represented 78.57% of capital, while the remaining 11 deals shared only 21.43%. This is a winner-take-most financing structure, not a broad-based startup boom.
Implantable BCIs remain the premium category. They captured 54.75% of capital and 37.50% of deals, giving the category a capital-share-to-deal-share ratio of 1.46. Investors are paying up for invasive or semi-invasive approaches despite higher procedural burden.
Non Invasive BCIs attract experimentation, but not yet equal conviction. The category represented 25.00% of deals but only 14.60% of capital. Most noninvasive approaches still need stronger proof before they receive implantable-scale checks.
Merge Labs is the major exception inside noninvasive BCI. Its $252M Seed round distorted the entire Seed-stage category. Without Merge, noninvasive BCI would look much more like a cluster of smaller technical bets.
Rehabilitation Interfaces show how one regional champion can reshape a category. BrainCo’s $286.3M financing gave the category 13.90% of total capital from just one deal. China’s BCI narrative appears more connected to rehabilitation and applied hardware than the U.S. implant-centric story.
Neuroprosthetics looks more balanced than most categories. It had a near-neutral capital-share-to-deal-share ratio of 0.97. That suggests investor dollars roughly matched deal activity, without the same level of distortion seen in implantables or rehabilitation interfaces.
Consumer Neurotech remains a small slice of serious capital formation. Neurable’s $35M Series A was the only qualifying consumer neurotech deal. Everyday EEG wearables may attract attention, but disclosed equity funding is still modest.
Pure software and data-layer BCI companies are under-financed. Neural Signal Processing had only one qualifying deal, brain.space’s $11M Series A. Hardware-heavy neural-interface companies are still attracting far more fundraising gravity.
North America anchors global BCI financing. The region captured 76.23% of disclosed capital and 62.50% of deals. The market remains centered on U.S.-style venture capital, clinical-device development, and celebrity-backed platform companies.
Asia-Pacific has fewer deals but meaningful scale. The region captured 20.81% of capital from 25.00% of deals. China in particular can produce very large BCI rounds when policy, industrial capital, and clinical ambition align.
Europe is visible in specialized clinical BCI, but absent from the largest platform rounds. INBRAIN’s $50M Series B was the only qualifying European round. That leaves Europe technically present but not setting the competitive tempo.
The median month had no disclosed Brain-Computer Interface deal. The market had 16 deals across 24 monthly buckets. BCI financing is episodic and milestone-driven rather than a steady monthly pipeline.
Sub-$50M rounds do not determine the strategic direction of the market. Capital excluding rounds above $50M totaled only $211.69M, or 10.28% of all disclosed capital. The smaller market exists, but it does not drive the category narrative.
Stage labels need adjustment in Brain-Computer Interface. Seed-stage capital looked large because Merge Labs raised an exceptional $252M first financing. Ordinary Seed checks and elite-platform Seed checks should not be interpreted the same way.
Repeat financings are a stronger signal than first checks. Subsense added $10M within the same year, and StairMed raised again after its February 2025 Series B. Investors re-underwrite quickly when a company sits inside a strategic technical theme.
Restoration use cases attract more capital than wellness or productivity claims. The dataset contains more funding for companies tied to paralysis, vision, prosthetics, and neurological function restoration. Capital is still rewarding concrete clinical endpoints over broad consumer enhancement.
Founder and ecosystem quality can substitute for clinical proof in rare cases. Merge Labs raised $252M early, before comparable clinical validation. In exceptional founder-led cases, AI-platform adjacency can change normal medtech financing rules.
The most useful evaluation rule is to look for four signals together. In Brain-Computer Interface, credible funding signals combine large capital, clinical path, manufacturing plan, and repeat investors. A large round without clinical direction, or a clinical claim without enough capital for execution, should be discounted.
BusinessWire (INBRAIN Neuroelectronics), Yahoo Finance (Precision Neuroscience), China Daily (StairMed Series B), BioSpace (Subsense Seed), PR Newswire (brain.space), PR Newswire (Phantom Neuro), Neuralink (Series E), BusinessWire (Synchron Series D), BusinessWire (Subsense additional financing), BusinessWire (Neurable), Yicai Global (BrainCo), Wired (Merge Labs), Science Corporation (Series C), MassDevice (Gestala), PR Newswire (StairMed strategic financing), BusinessWire (Axoft)
Related blog posts
- A complete overview of funding deals in the Brain-Computer interface market
- The most heavily funded startups in the Brain-Computer interface market
- The highest-valued startups in the Brain-Computer interface market
